This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

hyperlink,10000

I HAVE EGPA AND A WAY FORWARD

https://gskpro-com-preprod-cf5.gdsgsk.com/en-us/products/nucala/about/,1000

NUCALA: The first and ONLY anti-IL-5 for
hypereosinophilic syndrome (HES)

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable nonhematologic secondary cause.

Primary Endpoint Results:
Proportion of patients who experienced HES flare(s)* during the 32-week study or withdrew: NUCALA 28% vs placebo 56%, P=0.002.

Study Description:
32-week study comparing NUCALA 300 mg subcutaneous every 4 weeks to placebo, each added to stable HES therapy, in 108 patients aged ≥12 years with HES. Patients experienced ≥2 HES flares in the past 12 months and had a blood eosinophil count of ≥1000 cells/μL at screening.

*HES flare: Worsening of clinical signs/symptoms or increased eosinophils (on ≥2 occasions), resulting in an escalation/addition of oral corticosteroids (OCS) or cytotoxic or immunosuppressive therapy.

Anti-IL-5=anti-interleukin-5.